Evidence map›Paper›PMID 40066386›Full record

ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2025

Allergen Immunotherapy in Autoimmune Terrain: A Case Study.

Shambo S Samajdar, Saibal Moitra, Shatavisa Mukherjee, Jyotirmoy Pal, Shashank R Joshi

Abstract read
In one paragraph

Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shambo S SamajdarDiabetes and Allergy-Asthma Therapeutics Specialty Clinic, Kolkata, India.ORCID 0009-0004-1388-1131
Saibal MoitraAllergy & Immunology, Apollo Gleneagles Hospital, Kolkata, India.
Shatavisa MukherjeeDepartment of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, MD, West Bengal India.
Jyotirmoy PalDepartment of Medicine, Sagar Dutta Medical College and Hospital, Kolkata, West Bengal India.
Shashank R JoshiDepartment of Endocrinology, Joshi Clinic, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergen immunotherapy (AIT), or specific immunotherapy (SIT), is an effective treatment for inducing immune tolerance to specific allergens. It is widely used for allergic rhinitis, conjunctivitis, asthma, and Hymenoptera venom allergies, with recent applications to food allergies and atopic dermatitis. Despite its benefits, the use of SIT in patients with autoimmune diseases is controversial due to concerns about its potential to induce or exacerbate autoimmune conditions. This report examines a case of autoimmune hypothyroidism developing during AIT and the management decisions involved. A 26-year-old female with a history of moderate to severe persistent allergic rhinitis and childhood asthma presented with severe malaise, weakness, and fatigue over the past three months. She had a family history of asthma and allergic rhinitis. The patient had been on AIT for six months and was using intranasal fluticasone furoate nasal spray daily. Initial laboratory investigations prior to AIT showed normal thyroid function. Three months into AIT, she developed hypothyroidism, confirmed by elevated TSH levels and positive anti-TPO antibodies. A causality assessment suggested a "possible" link between AIT and hypothyroidism. However, a risk-benefit analysis favored the continuation of AIT along with the initiation of L-thyroxine therapy. After six months of thyroid hormone replacement, her TSH levels normalized, and her allergic rhinitis symptoms significantly improved. This case underscores the complexity of managing coexisting allergic and autoimmune conditions. The decision to continue AIT, despite the onset of hypothyroidism, was based on a thorough risk-benefit analysis, emphasizing the need for personalized treatment plans. Understanding the immunological mechanisms, particularly the balance between Th17 and Treg cells, is crucial. Neutrophils play a significant role as both effectors and modulators of immune responses. The clinical pharmacologist's recommendation was informed by these factors and the manageable nature of hypothyroidism with hormone replacement therapy. The continuation of AIT was justified by its benefits in managing allergic rhinitis and the manageable nature of hypothyroidism with hormone therapy. This case highlights the importance of personalized medicine and continuous monitoring in treatment decisions for patients with coexisting conditions.

Indexed as

Allergen immunotherapyAllergic rhinitisAutoimmune hypothyroidismClinical pharmacologyRisk-benefit analysis

Identifiers

PMID40066386
PMCPMC11890459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.